Seegene Collaborates with MS for a 'World Without Disease'... Promotes 'Diagnostic Technology Sharing Project'

Seegene announced on the 24th that it will collaborate with Microsoft (MS) to promote a technology-sharing project aimed at realizing the vision of a "world without disease."

Elena Bonfiglioli, Head of Microsoft Global Health and Life Sciences, and Cheon Jong-yoon, CEO of Seegene (from left), attended the signing ceremony of the memorandum of understanding (MOU) on strategic cooperation for the technology sharing project held in London, UK, on the 23rd (local time), and took a commemorative photo after signing.
[Photo by Seegene]

Seegene revealed on the 24th that it held a signing ceremony for this strategic cooperation in London, UK, on the 23rd (local time). Through collaboration with MS, Seegene plans to share its syndromic quantitative gene amplification (PCR) technology with global leading companies and accelerate the growth of the technology-sharing project that drives cross-industry innovation in the molecular diagnostics field. Additionally, by expanding the number of participating companies forming a global consortium, Seegene aims to provide optimal solutions worldwide to effectively respond to future pandemics and realize a "world free from all diseases." Seegene's syndromic PCR technology tests 14 pathogens that cause similar symptoms in a single tube, providing quantitative information on co-infections and the severity of symptoms.

To this end, Seegene will cooperate with MS's global healthcare team and jointly participate in the annual symposium of the technology-sharing project as well as other major events connecting current and potential partners. Within the first half of this year, a declaration ceremony will be held for the scientific community and other technology-sharing project partners to celebrate their shared vision.

The technology-sharing project is a global strategy promoted by Seegene to realize a "world without disease." It is a project where scientists and experts worldwide directly develop diagnostic reagents for various diseases in humans, animals, and plants using Seegene's development automation system (SGDDS) on-site. Seegene plans to form global consortium partnerships with over 100 companies representing each country and share its syndromic quantitative PCR technology. Partner companies in each country will establish local companies responsible for product development, production, and sales based on this technology.

Seegene's development automation system (SGDDS) will incorporate MS's cloud service 'Azure,' including Azure OpenAI Service, and introduce 'MS Fabric,' an AI-based unified analytics platform that allows everyone to access and manage data. Alongside this, 'MS 365 Copilot' will provide integrated AI-based services to enhance productivity as well as innovation and creativity.

Going forward, Seegene plans to explore future collaboration with MS in the medical sector for joint medical innovation research, including next-generation PCR data management and analysis. It also aims to improve the medical ecosystem through accurate early disease diagnosis, which forms the foundation for effective treatment and prevention.

Jong-Yoon Chun, CEO of Seegene, said, "Through strategic collaboration with MS, we have been able to establish a more systematic technology-sharing project model," adding, "We expect the synergy effect from cooperation between the two companies to open the path toward a world free from all diseases." Elena Bonfiglioli, Head of MS Global Health and Life Sciences, stated, "We support Seegene's vision to realize a 'world free from all diseases,' and in addition to collaborating on Seegene's digital transformation, we will work together to discover global partners and further strengthen the healthcare ecosystem."

This content was produced with the assistance of AI translation services.